Complement as a source of biomarkers in systemic lupus erythematosus: Past, present, and future Chau-Ching LiuJoseph M. AhearnSusan Manzi Invited Commentary Pages: 85 - 88
The efficacy of etanercept in ankylosing spondylitis Christopher T. Ritchlin Clinical Trials Report Pages: 95 - 95
The efficacy of etanercept in ankylosing spondylitis Christopher T. Ritchlin Clinical Trials Report Pages: 95 - 96
The efficacy of infliximab in ankylosing spondylitis Christopher T. Ritchlin Clinical Trials Report Pages: 96 - 96
Treatment guidelines for ankylosing spondylitis Christopher T. Ritchlin Clinical Trials Report Pages: 96 - 97
New directions in classification and outcome assessment in ankylosing spondylitis Désirée van der Heijde OriginalPaper Pages: 98 - 101
Imaging in spondyloarthropathies Mikayel GrigoryanFrank W. RoemerHarry K. Genant OriginalPaper Pages: 102 - 109
Scleroderma renal crisis: New insights and developments Elisa Y. RhewWalter G. Barr OriginalPaper Pages: 129 - 136
The pathogenesis of fibrosis and renal disease in scleroderma: Recent insights from glomerulosclerosis Sungchun LeeSohee LeeKumar Sharma OriginalPaper Pages: 141 - 148
Vascular injury in systemic sclerosis: Angiotensin-converting enzyme insertion/deletion polymorphism Cinzia FatiniSerena GuiducciMarco Matucci-Cerinic OriginalPaper Pages: 149 - 155
Antibodies in scleroderma: Direct pathogenicity and phenotypic associations Lorinda ChungPaul J. Utz OriginalPaper Pages: 156 - 163
Antifibrotic therapy in scleroderma: Extracellular or intracellular targeting of activated fibroblasts? John Varga OriginalPaper Pages: 164 - 170